Literature DB >> 11337374

Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?

R Shah1, N R Mucci, A Amin, J A Macoska, M A Rubin.   

Abstract

Postatrophic hyperplasia (PAH) of the prostate gland often demonstrates overlapping histological features with prostatic adenocarcinoma (PCA). These features include small acinar growth and enlarged nuclei with prominent nucleoli. Recent work has demonstrated that PAH is a proliferative, noninvoluting lesion. PAH is also histologically distinct from simple atrophy (SA), which has intermediate- to large-sized glands, minimal cytoplasm, and inconspicuous nuclei. However, despite overlapping features between PAH and PCA, high-grade prostatic intraepithelial neoplasm (HGPIN) is still considered the only direct neoplastic precursor to PCA. HGPIN resembles PCA in its topographic distribution, cytological appearance, and molecular alterations including chromosome 8p loss and chromosome 8 centromeric gain. To examine the hypothesis that PAH is the earliest histologically distinct precursor to HGPIN or PCA, the frequency, distribution, proliferative state, and chromosome 8 gain of benign prostate, SA, PAH, HGPIN, and PCA were analyzed. Forty radical prostatectomy specimens from men with clinically localized PCA were systematically analyzed. Proliferation was determined by Ki-67 immunohistochemistry (MIB-1) on formalin-fixed, paraffin-embedded tissue and quantified by digital image analysis from a total of 5,510 sample areas with benign, SA, PAH, HGPIN, and PCA. A tissue microarray was constructed to evaluate 8c gain using interphase fluorescence in situ hybridization. SA foci (n = 129) and PAH foci (n = 114) were identified in the 40 cases of which 74% (95 of 129) and 88% (100 of 114) were seen in the peripheral zone, respectively (P = 0.006). PAH and SA were identified adjacent to PCA in 28% (32 of 114) and 14% (18 of 129) of foci examined, respectively (P = 0.007). The median number of proliferating nuclei increased significantly from benign (1.20%), SA (2.67%), PAH (3.62%), HGPIN (6.14%), to PCA (12.00%) (P < 0.001). The median percentage of nuclei with more than three centromeric probe signals (chromosome 8c gain) for SA, HGPIN, PAH, and PCA were 2.1, 2.8, 4.0, and 6.0%, respectively, as compared to benign prostate with 1.3% (P = 0.006). In conclusion, the present study identified a strong topographic association between PAH and PCA. PAH is also seen often to be closely associated with chronic inflammation. Proliferation of PAH is significantly greater than benign prostatic epithelium and SA but less than HGPIN or PCA. Gain of 8c is significantly greater in PAH than benign prostate, SA, and even HGPIN. These findings demonstrate a strong association between PAH and PCA, supporting its role as a neoplastic precursor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337374      PMCID: PMC1891965          DOI: 10.1016/S0002-9440(10)64132-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Atrophy and hyperplasia in the prostate proper.

Authors:  L M FRANKS
Journal:  J Pathol Bacteriol       Date:  1954-10

2.  Ki-67 expression in early prostate cancer and associated pathological lesions.

Authors:  M R Feneley; M P Young; C Chinyama; R S Kirby; M C Parkinson
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

3.  Prostatic atrophy: an autopsy study of a histologic mimic of adenocarcinoma.

Authors:  A Billis
Journal:  Mod Pathol       Date:  1998-01       Impact factor: 7.842

4.  Atrophy and regeneration in the pathogenesis of prostatic carcinoma.

Authors:  I Liavåg
Journal:  Acta Pathol Microbiol Scand       Date:  1968

5.  8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer.

Authors:  J A Macoska; T M Trybus; K J Wojno
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

6.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

Authors:  L Bubendorf; J Kononen; P Koivisto; P Schraml; H Moch; T C Gasser; N Willi; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

7.  Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site.

Authors:  M A Prasad; T M Trybus; K J Wojno; J A Macoska
Journal:  Genes Chromosomes Cancer       Date:  1998-11       Impact factor: 5.006

Review 8.  Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma.

Authors:  J Qian; R B Jenkins; D G Bostwick
Journal:  Anal Quant Cytol Histol       Date:  1998-10       Impact factor: 0.302

9.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.

Authors:  J Qian; D G Bostwick; S Takahashi; T J Borell; J F Herath; M M Lieber; R B Jenkins
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

10.  The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.

Authors:  K J Wojno; J I Epstein
Journal:  Am J Surg Pathol       Date:  1995-03       Impact factor: 6.394

View more
  26 in total

1.  Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.

Authors:  Sabina Davidsson; Michelangelo Fiorentino; Ove Andrén; Fang Fang; Lorelei A Mucci; Eberhard Varenhorst; Katja Fall; Jennifer R Rider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-27       Impact factor: 4.254

2.  Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.

Authors:  Rita Garcia-Parra; David Wood; Rajal B Shah; Javed Siddiqui; Hero Hussain; Hyunjin Park; Timothy Desmond; Charles Meyer; Morand Piert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-16       Impact factor: 9.236

Review 3.  The role of the prostate in male fertility, health and disease.

Authors:  Paolo Verze; Tommaso Cai; Stefano Lorenzetti
Journal:  Nat Rev Urol       Date:  2016-06-01       Impact factor: 14.432

4.  Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.

Authors:  Geert J L H van Leenders; Wesley R Gage; Jessica L Hicks; Bianca van Balken; Tilly W Aalders; Jack A Schalken; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 5.  Molecular markers in prostate cancer. Part I: predicting lethality.

Authors:  Sachin Agrawal; William D Dunsmuir
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

6.  BK virus as a cofactor in the etiology of prostate cancer in its early stages.

Authors:  Dweepanita Das; Kirk Wojno; Michael J Imperiale
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

Review 7.  Prostate cancer and chronic prostatitis.

Authors:  Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

8.  Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection.

Authors:  Masashi Nakayama; Christina J Bennett; Jessica L Hicks; Jonathan I Epstein; Elizabeth A Platz; William G Nelson; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.

Authors:  Rita Ghosh; Gretchen E Garcia; Katherine Crosby; Hiroyasu Inoue; Ian M Thompson; Dean A Troyer; Addanki P Kumar
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.

Authors:  Morand Piert; Hyunjin Park; Asra Khan; Javed Siddiqui; Hero Hussain; Thomas Chenevert; David Wood; Timothy Johnson; Rajal B Shah; Charles Meyer
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.